ADVAGRAF®
ApprovedCompleted 0 watching 0 views this week🔥 Hot
85
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 2✓
Phase 35
ApprovedIndication / Disease
Liver Transplantation
Conditions
Liver Transplantation
Trial Timeline
Mar 22, 2016 → Dec 14, 2017
NCT ID
NCT03423225About ADVAGRAF®
ADVAGRAF® is a approved stage product being developed by Astellas Pharma for Liver Transplantation. The current trial status is completed. This product is registered under clinical trial identifier NCT03423225. Target conditions include Liver Transplantation.
Hype Score Breakdown
Clinical
30
Activity
20
Company
10
Novelty
10
Community
12
Clinical Trials (3)
| NCT ID | Phase | Status |
|---|---|---|
| NCT03423225 | Approved | Completed |
| NCT04761731 | Approved | Completed |
| NCT02161237 | Approved | Completed |
Competing Products
20 competing products in Liver Transplantation